The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.
 
Jong Chul Park
Honoraria - Coherus Biosciences; MitoImmune; Selecxine
Consulting or Advisory Role - Hanall Biopharma; Hanmi Pharma
Research Funding - A2 Bio (Inst); A2 Biotherapeutics (Inst); Alentis Therapeutics (Inst); ALX Oncology (Inst); Ankyra Therapeutics (Inst); CUE Biopharma (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst)
 
Marcus Butler
Honoraria - Bristol-Myers Squibb; Medison; Merck; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Brendan Curti
Honoraria - Asante Health; St Joseph Hospital
Consulting or Advisory Role - Merck; Werewolf Therapeutics
Research Funding - Ankyra Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Asante Health; St Joseph Hospital
 
Gail Iodice
Employment - Ankyra Therapeutics
Stock and Other Ownership Interests - Ankyra Therapeutics
 
Danielle Pastor
No Relationships to Disclose
 
Joseph Elassal
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Ankyra Therapeutics
Travel, Accommodations, Expenses - Ankyra Therapeutics
 
Howard Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
John Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; AXIO Research; Boxer Capital; Bristol Myers Squibb; CytomX Therapeutics; DermTech; Engage Health Media; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lumira Capital Investment Management; Lytix Biopharma; Magnolia Innovation; Merck; Mural Oncology; Natera; Novartis; OncoCyte; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; Takeda; Valar Labs; Zola Therapeutics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Lytix Biopharma (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron